3 Stocks That Have Seen Better Days

Steadymed stock is sinking after the FDA rejected a new drug application

by Katie Coburn

Published on Aug 31, 2017 at 2:22 PM

U.S. stocks are trading higher this afternoon, getting a lift from the latest economic data. Three stocks in the spotlight today that have seen better days, however, are bank stock Wells Fargo & Co (NYSE:WFC), footwear and apparel retailer Genesco Inc. (NYSE:GCO), and pharmaceutical company Steadymed Ltd (NASDAQ:STDY). Here's a quick look at what's moving shares of WFC, GCO, and STDY.

Wells Fargo Finds More Phony Accounts

Wells Fargo stock is down 0.8% to trade at $50.95, after the company found 70% more unauthorized accounts than previously thought. The findings come almost a year after the bank fired thousands of employees over the fake account scandal

Now down 7.5% year-to-date, WFC is pacing for its lowest close since November, and is poised to close below its 20-month moving average for only the second time in 2017. Still, roughly a third of the 22 analysts following the stock rate it a "buy" or better, leaving room for bearish brokerage notes, should the shares extend their decline. 

Jefferies Cuts GCO's Price Target Nearly in Half After Earnings Miss

Shares of Genesco are down 16.1% to trade at $21.40, and earlier hit a seven-year low of $21.15, after the company reported lower-than-expected second-quarter earnings and missed revenue forecasts. As a result, Jefferies cut its price target on GCO nearly in half, to $27 from $48.

Genesco stock is today's worst percentage loser on the New York Stock Exchange, and is down almost 65% year-to-date. Shorts are likely cheering today's decline, as short interest represents roughly 9% of GCO's total available float, or six times the stock's average daily trading volume. Today, however, Genesco stock is on the short-sale restricted (SSR) list.

STDY Stock Sinks After FDA Letter

Steadymed stock is down a whopping 34% to trade at $3.90, after the U.S. Food and Drug Administration (FDA) turned down the company's new drug application for Trevyent, which is designed to treat a rare lung disease. The FDA is asking Steadymed to provide more information on the drug.

Today's plunge has the stock on pace for its worst-ever one-day decline, and ranks STDY as the biggest percentage loser on the Nasdaq. STDY has lost more than half of its value since hitting an annual high of $9.70 on April 3, and could close the month beneath its 20-month moving average for the first time since January. Some bears jumped ship a little too early, as short interest on STDY has decreased by 18% over the past two weeks. Short interest, however, still represents more than nine times the stock's average daily trading volume.


a schaeffer's exclusive

PLAY TRENDS LIKE A PRO!

5 tips to leverage profits in this FREE insider report!


 
 

Partnercenter


NEW! Explore Schaeffer’s Partners' deals and get connected to top online brokerages with deals tailored exclusively for our readers.  Get answers to your questions regarding transfer fees, commission rates, programs and available discounts related to online trading services.

MORE | MARKETstories


The Trend Minting Millionaires -- But Who Is Really Paying?
Porter Stansberry is making a concerning prediction.
Roller Coaster Week Defined by Trade Headlines, Jobs Report
The Dow made outsized moves in both directions this week
Needham is Buying Trade Desk Ahead of the 2020 Election
Trade Desk stock has more than doubled in 2019
The Trend Minting Millionaires -- But Who Is Really Paying?
Porter Stansberry is making a concerning prediction.